在精密癌症医学的背景下,他类药物:需要考虑的重要因素
Francisco Alejandro Lagunas-Rangel1
1Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga, LV-1006, Latvia. francisco.lagunas@cinvestav.mx.
Medical oncology (Northwood, London, England)
|October 31, 2025
概括
类药物通过诱导细胞死亡和改变瘤环境,显示出抗癌潜力. 需要精准医学来优化它们在癌症治疗中的使用,考虑到药物特性和患者遗传学.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物重用 药物重用
背景情况:
- 广泛用于高胆固醇血症的他类药物表现出抗癌性质,如诱导亡和瘤微环境调节.
- 这些特性表明,他类药物是癌症治疗中重新使用的有希望的候选人.
研究的目的:
- 审查制定他类药物的精确癌症医学框架的关键考虑因素.
- 强调在将他类药物整合到瘤学中需要量身定制的方法.
主要方法:
- 关于他类药物的抗癌作用的临床前和临床数据的审查.
- 分析影响他类药物的疗效的因素,包括化学性质,药理动力学和遗传变异性.
- 探索生物标志物,治疗度,药物协同作用和输送技术.
主要成果:
- 在瘤学中对他类药物的临床评估有限,主要使用中等强度的治疗方案.
- 新出现的证据表明,剂量和时间依赖的抗癌活性,在他类型之间存在差异.
- 在癌症中确定精确的他类药物治疗的关键因素.
结论:
- 类药物对癌症治疗有前途,但精准医学方法对于有效的整合至关重要.
- 需要进一步的研究来优化癌症患者的他类药物选择,剂量和输送.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Factors Affecting Protein-Drug Binding: Patient-Related Factors
298
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
298
Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Coronary Artery Disease IV: Preventive Measures
579
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
579


